Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma.
Rosalinda TerminiDavid ZihalaEvangelos TerposAlbert Perez-MontañaTomas JelinekMarc-Steffen RaabNiels WeinholdElias Karl MaiAnna Luise GrabJill CorreFrançois VergezAntonio SaccoMarco ChiariniViviana GiustiniAlessandra TucciSara RodriguezCristina MorenoCristina PerezCatarina MaiaEsperanza Martín-SánchezCamilla GuerreroCirino BottaJuan-José GarcésAitziber LopezLuis-Esteban Tamariz-AmadorFelipe ProsperJoan BargayMaria-Elena CabezudoEnrique María OcioRoman HájekJoaquin Martinez LopezFernando SolanoRebeca IglesiasArtur PaivaCatarina GeraldesHelena VitoriaClara GomezFelipe De ArribaHeinz LudwigAntoni Garcia-GuiñonMaría CasanovaAdrian AlegreValentín CabañasMaialen SirventAlbert OrtiolJavier de la RubiaJose-Ángel Hernández-RivasLuis PalomeraMaria SarasaPablo RiosNoemi PuigMaria-Victoria Mateos-MantecaJuan A Flores-MonteroAlberto OrfaoHartmut GoldschmidtHerve Avet-LoiseauAldo M RoccaroJesús San F MiguelJuan José Lahuertanull nullPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
This study showed that CTCs outperform BM PCs for assessing tumor burden. Additional analysis in larger series are needed to define a consensus cutoff of CTCs for minimally invasive stratification of SMM.